|
[1]Schuppan D,Friedman S.Antifibrotic therapy:Translation into the clinic[J].Hepatology,2009,50(Suppl 4):100A.
|
|
[2]Schuppan D,Popov Y.Targeting liver fibrosis:Strategies for development and validation of antifibrotic therapies[J].Hepatology,2009,50(4):1294-1306.
|
|
[3]Wells RG.Liver fibrosis:challenges of the new era[J].Gastroenterology,2009,136(2):387-388.
|
|
[4]蔡卫民.认识肝纤维化[J].健康研究,2010,30(3):161-166.
|
|
[5]Taura K,Miura K,Iwaisako K,et al.Hepatocytes fo not undergo epithelial-mesenchymal transition in liver fibrosis in mice[J].Hepatology,2010,51(3):1027-1036.
|
|
[6]Wells RG.The epithelial-to-mesenchymal transition in liver fibrosis:Here today,gone tomorrow?[J].Hepatology,2010,51(3):737-740.
|
|
[7]Dranoff JA,Wells RG.Portal fibroblasts:Underappreciated mediators of biliary fibrosis[J].Hepatology,2010,51(4):1438-1444.
|
|
[8]Zhang DW,Bian H.No contribution to liver fibrosis,but possible carcinogenesis?[J].Hepatology,2010,51(4):1468-1469.
|
|
[9]高建蓉,刘焱文,李昌煜,等.鳖甲抗肝纤维化活性物质的筛选与分离鉴定[J].中华肝脏病杂志,2010,18(5):346-352.
|
|
[10]Weng H,Mertens PR,Gressner AM,et al.IFNγabrograters profibrogenic TGFβsignaling in liver by targeting expression of inhibitory and receptor Smads[J].J Hepatol,2007,46(2):295-303.
|
|
[11]Saile B,Eisenbach C,El-Armouche H,et al.Antiapoptotic effect of interferon-alpha on hepatic stellate cells(HSC):a novel pathway of IFN-alpha signal transduction via Janus kinase 2(JAK2)and caspase-8[J].Eur J Cell Biol,2003,82(1):31-41.
|
|
[12]Fickert P,Stoger U,Fuchsbicher A,et al.A new xenobiotac-induced of sclerosing cholangitis and biliary fibrosis[J].Am J pathol,2007,171(2):527-536.
|
|
[13]翁红雷,蔡卫民,汪国运,等.γ-干扰素抗大鼠肝纤维化的初步研究[J].中西医结合肝病杂志,1998,8(2):91-93.
|
|
[14]翁红雷,蔡卫民,汪国运,等.不同剂量γ-干扰素治疗大鼠实验性肝纤维化疗效研究[J].中华传染病,2001,19(5):26-29.
|
|
[15]王宝恩,王志实,殷葭荑,等.实验性免疫性肝纤维化模型的研究[J].中华医学杂志,1989,69(2):503-505.
|
|
[16]陈峰,蔡卫民,陈智,等.日本血吸虫病兔胶原合成与降解转录水平的研究[J].中国寄生虫学与寄生虫病,2001,19(5):76-79.
|
|
[17]汪国运,蔡卫民,王金泉,等.肝纤维组织学量化诊断的实验研究[J].中华肝脏病杂志,1998,6(4):201-202.
|
|
[18]陶君,夏琦,蔡卫民,等.安珐特与γ-干扰素抗肝纤维化比较研究[J].中西医结合肝病杂志,2006,16(6):358-376.
|
|
[19]Sobrevals L,Rodriguez C,Romero-Trevejo JL,et al.Insulin-like growth factor 1 gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats[J].Hepatology,2010,5(3):912-921.
|
|
[20]Moreno M,Chaves JF,Sancho-Bru P,et al.Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans[J].Hepatology,2010,51(3):974-985.
|
|
[21]Douglass A,Wallace K,Parr R,et al.Antibody-targeted myofibroblast apoptosis reduces fibrosis during sustained liver injury[J].J Hepatol,2008,49(1):88-98.
|
|
[22]Sato Y,Murase K,Kato J,et al.Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone[J].Nat Biotechnol,2008,26(4):431-442.
|
|
[23]Schoemaker MH,Rots MG,Beljaars L,et al.PDGF-receptor beta-targeted adenovirus redirects gene transfer from hepatocytes to activated stellate cells[J].Mol Pharm,2008,5(3):399-406.
|
|
[24]Rockey DC.Current and future anti-fibrotic therapies for chronic liver disease[J].Clin Liver Dis,2008,12(4):939-962.
|
|
[25]Mannaerts I,Nuytten NR,Rogiers V,et al.Chronic administration of valproic acid inhibits activation of mouse hepatic stellate cell in Vitro and in Viro[J].Hepatology,2010,51(2):603-614.
|
|
[26]Ikura Y,Iwasa Y,Ueda M.Valproic acid administration for hepatic fibrosis:a balance between antifibrotic efficacy and hepatotoxicity[J].Hepatology,2010,51(6):2227-2228.
|
|
[27]Moreno M,Gonzalo T,Kok RJ,et al.Reduction of advanced liver fibrosis by short-term targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats[J].Hepatology,2010,51(3):942-952.
|
|
[28]McHutchison J,Goodman Z,Patel K,et al.Farglitazar lacks antifibrotic activity in patients with chronic hepatitis C infection[J].Gastroenterology,2010,138(4):1365-1373.
|
|
[29]Harrison SA.Thiazolidinedione therapy for nonalcoholic steatohepatitis:go,stop,or proceed with caution?[J].Hepatology,2010,51(2):366-369.J Clini Hepatol,March 2011,Vol.27,No.3
|
|
[30] 任光辉.临床血吸虫病学[M].北京:人民卫生出版社,2009:273-302.
|
|
[31]Fontana RJ.Side effects of long-term oral antiviral therapy for hepatitis B[J].Hepatology,49(5):s185-195.
|
|
[32]European Association For The Study of the Liver.EASL Clinical Practice Guidelines:management of chronic hepatitis B[J].J Hepatol,2009,50(2):227-242.
|
|
[33]Lok AS,McMahon BJ.Chronic hepatitis B:update[J].Hepatology,2009,50:661-662.
|
|
[34] 任红.慢性乙型肝炎治疗的热点和难点[J].中华肝脏病杂志,2009,17(10):721.
|
|
[35]Weng HL,Wang BE,Jia JD,et al.Effect of IFNγon hepatic fibrosis in chronic hepatitis B virus infection:A randomized controlled study[J].Chin Gastroenterol Hepatol,2005,3(8):819-828.
|
|
[36]Prockros P,Jeffers L,Afdhal N,et al.Final results of A do-uble-blind,placebo-controlled trial of the antifibrotic efficacy of interferon-rlb in chronic hepatitis C patients with advanced fibrosis or cirrhosis[J].Hepatology,2007,45(1):569-578.
|
|
[37]Weng HL,Ciuclan L,Liu Y,et al.Profibrogenic transforming growth factor-beta/activin receptor-like kinase 5 signaling via connective tissue growth factor expression in hepatocytes[J].Hepatology,2007,46(4):1257-1270.
|
|
[38]陈煜,王宝恩,贾德东,等.慢性乙型肝炎肝纤维化程度无创伤评估[J].中华肝脏病杂志,2003,11(5):354-357.
|
|
[39]Garcia-Tsao G,Friedmen S,Iredale J,et al.Now there are many(stages)where before there was one:In search of a pathophysiological classification of cirrhosis[J].Hepatology,2010,51(4):1095-1106.
|
|
[40] 中华肝病学会.肝纤维化诊断及疗效评估共识[J].中华肝脏病杂志,2006,10(5):327-328.
|
|
[41]中西医结合学会肝病分会.肝纤维化中西结合诊疗指南[J].中华肝脏病杂志,2006,14(11):866-870.
|
|
[42]翁红雷,蔡卫民,王宝恩,等.重组干扰素γ治疗慢性乙型肝炎肝纤维化临床研究[J].中华医学杂志,2003,83(11):943-947.
|
|
[43]Muir AJ,Sylvestre PB,Rockey DC.Interferon gamma-1b for the treatment of fibrosis in chronic hepatitis C infection[J].J Viral Hepat,2006,13(2):322-328.
|
|
[44]Rockey DC,Caldwell SH,Goodman,et al.Liver biopsy[J].Hepatology,2009,49(3):1017-1044.
|
|
[45]Castéra L,Foucher J,Bernard PH,et al.Pitfalls of liver sfiffness measurement:A 5-year prospective study of 13,369 examinations[J].Hepatology,2010,51(3):828-835.
|
|
[46]Weng HL,Liu Y,Chen JL,et al.The etiology of liver da-mage imparts cytokines transforming growth factor betal or interleukine-13 as driving forces in fibrogenesis[J].Hepatology,2009,50(1):230-243.
|
DownLoad: